Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Published In:
- The lancet. Diabetes & endocrinology, 13(10), 838-847 (2025)
- Authors:
- Lim, Soo(4), Buranapin, Supawan, Bao, Xiaolei, Quiroga, María, Park, Kyung Hee, Kang, Jee-Hyun, Rinnov, Anders Rasmussen, Suwanagool, Arisara
- Database ID:
- RPEP-12158
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12158APA
Lim, Soo; Buranapin, Supawan; Bao, Xiaolei; Quiroga, María; Park, Kyung Hee; Kang, Jee-Hyun; Rinnov, Anders Rasmussen; Suwanagool, Arisara. (2025). Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.. The lancet. Diabetes & endocrinology, 13(10), 838-847. https://doi.org/10.1016/S2213-8587(25)00164-0
MLA
Lim, Soo, et al. "Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.." The lancet. Diabetes & endocrinology, 2025. https://doi.org/10.1016/S2213-8587(25)00164-0
RethinkPeptides
RethinkPeptides Research Database. "Once-weekly semaglutide 2·4 mg in an Asian population with o..." RPEP-12158. Retrieved from https://rethinkpeptides.com/research/lim-2025-onceweekly-semaglutide-24-mg
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.